Related Experiment Video
Updated: Oct 17, 2025
08:45
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
6.4K
Patidegib in Dermatology: A Current Review
Terenzio Cosio1, Monia Di Prete2,3, Cosimo Di Raimondo1
1Dermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, Via Montpellier, 1 00133 Rome, Italy.
International Journal of Molecular Sciences
|October 13, 2021
Summary
Topical patidegib gel shows safety and efficacy for early-stage basal cell carcinoma. This targeted therapy reduces tumor burden with fewer side effects than systemic treatments, improving patient management.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Basal cell carcinoma (BCC) is a common skin cancer, often locally destructive.
- Surgery is standard but less effective for advanced BCC.
- Hedgehog pathway inhibitors offer new therapeutic options for advanced BCC.
Purpose of the Study:
- To review the use of patidegib for advanced and recurrent aggressive basal cell carcinomas.
- To evaluate patidegib's safety, tolerability, and efficacy.
Main Methods:
- Comprehensive literature search for English language human studies.
- Included seven trials reporting patidegib application.
Main Results:
- Topical and systemic patidegib were safe and effective in treatment-naïve patients with stage II and III BCC.
- No significant benefit was observed in stage IV disease or in patients previously treated with systemic therapy.
Conclusions:
- Patidegib 2% gel offers a localized treatment option without systemic adverse effects common to other Hedgehog pathway inhibitors.
- Personalized treatment strategies, including pharmacogenomics, are crucial for optimal management of basal cell carcinoma.
Related Concept Videos
01:42Phosphoinositides and PIPs
9.0K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
9.0K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
282
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
282
01:29Inflammatory Bowel Disease IV: Pharmacological Management
240
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
240
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
753
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
753
02:58Regulated Protein Degradation
7.9K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.9K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
284
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
284